Remove 2022 Remove Competition Remove Physicians
article thumbnail

ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition

Pharmaceutical Technology

A global Phase III TROPiCS-02 study evaluated the use of Trodelvy in comparison to physicians’ choice of chemotherapy in 543 HR+/HER2- metastatic breast cancer patients who were previously treated with endocrine therapy, CDK 4/6 inhibitors and at least two lines of chemotherapy. months) versus physicians’ choice chemotherapy (11.2

article thumbnail

How provider organizations can use data analytics to increase physician engagement

Clarify Health

Physician engagement is a crucial factor in the success and growth of healthcare organizations. Engaged physicians are not only more likely to deliver high-quality care to patients, but also play a pivotal role in driving operational efficiency and innovation. Areas to focus on include: Patient outcomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Competition starts to heat up. The post Competition is on the horizon for costly narcolepsy treatments appeared first on. About the author.

article thumbnail

Proposed Changes to Remote Therapeutic Monitoring Reimbursement in the Proposed 2023 Medicare Physician Fee Schedule

Nixon Gwilt Law

Every summer when the Centers for Medicare and Medicaid Services (“CMS”) releases the Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”), the Nixon Gwilt Law (“NGL”) team excitedly opens the two-thousand-something-page PDF and immediately keys “ctrl+F” (or command+F for us Mac users) to jump to our most anticipated section(s).

article thumbnail

ESMO 2022: Ten key takeaways on Europe’s top oncology event

Clarivate

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Read on to for insights from our analysts on: Global highlights from ESMO 2022. Key ESMO 2022 highlights from Mainland China. Seven global highlights from ESMO 2022.

article thumbnail

The AMJEVITA impact: Innovative U.S. biosimilar pricing models

Clarivate

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. In 2022, it made its manufacturer, AbbVie, $21.2bn. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. from 91% in 2023 to 36% by 2031.

article thumbnail

How RPM Companies Can Leverage the New Remote Therapeutic Monitoring CPT Codes Expected in 2022

Nixon Gwilt Law

If you are in the digital health industry, particularly the remote patient monitoring (“RPM”) space, you have likely heard of the remote therapeutic monitoring (“RTM”) codes finalized in the 2022 Medicare Physician Fee Schedule Final Rule (the “Final Rule”). blood pressure monitors and pulse oximeters) as a new service line?